Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Texas A&M University Health Science Center College of Medicine, Temple, Texas.
Pediatrics. 2023 Apr 1;151(4). doi: 10.1542/peds.2022-059922.
Infants and children are at increased risk of severe influenza virus infection and its complications. Influenza vaccine effectiveness (VE) varies by age, influenza season, and influenza virus type/subtype. This study's objective was to examine the effectiveness of inactivated influenza vaccine against outpatient influenza illness in the pediatric population over 9 influenza seasons after the 2009 A(H1N1) pandemic.
During the 2011-2012 through the 2019-2020 influenza seasons at outpatient clinics at 5 sites of the US Influenza Vaccine Effectiveness Network, children aged 6 months to 17 years with an acute respiratory illness were tested for influenza using real-time, reverse-transcriptase polymerase chain reaction. Vaccine effectiveness was estimated using a test-negative design.
Among 24 148 enrolled children, 28% overall tested positive for influenza, 3017 tested positive for influenza A(H3N2), 1459 for influenza A(H1N1)pdm09, and 2178 for influenza B. Among all enrollees, 39% overall were vaccinated, with 29% of influenza cases and 43% of influenza-negative controls vaccinated. Across all influenza seasons, the pooled VE for any influenza was 46% (95% confidence interval, 43-50). Overall and by type/subtype, VE against influenza illness was highest among children in the 6- to 59-month age group compared with older pediatric age groups. VE was lowest for influenza A(H3N2) virus infection.
Analysis of multiple seasons suggested substantial benefit against outpatient illness. Investigation of host-specific or virus-related mechanisms that may result in differences by age and virus type/subtype may help further efforts to promote increased vaccination coverage and other influenza-related preventative measures.
婴儿和儿童患严重流感病毒感染及其并发症的风险增加。流感疫苗的有效性(VE)因年龄、流感季节和流感病毒类型/亚型而异。本研究的目的是在 2009 年 A(H1N1)大流行后的 9 个流感季节后,检查灭活流感疫苗对儿科人群门诊流感疾病的有效性。
在美国流感疫苗有效性网络的 5 个站点的门诊诊所,在 2011-2012 年至 2019-2020 年流感季节期间,对患有急性呼吸道疾病的 6 个月至 17 岁儿童使用实时逆转录聚合酶链反应检测流感。使用阴性测试设计估计疫苗的有效性。
在 24148 名入组儿童中,总体有 28%检测出流感阳性,3017 例为 A(H3N2)流感阳性,1459 例为 A(H1N1)pdm09 流感阳性,2178 例为 B 流感阳性。在所有入组者中,总体有 39%接种了疫苗,其中 29%的流感病例和 43%的流感阴性对照接种了疫苗。在所有流感季节中,任何流感的总体 VE 为 46%(95%置信区间,43-50)。总体而言,按类型/亚型划分,6 至 59 个月龄儿童的流感疫苗有效性最高,而年龄较大的儿科人群的流感疫苗有效性较低。流感 A(H3N2)病毒感染的 VE 最低。
对多个季节的分析表明,门诊疾病有很大的益处。对可能因年龄和病毒类型/亚型而导致差异的宿主特异性或病毒相关机制进行调查,可能有助于进一步努力提高疫苗接种覆盖率和其他流感相关预防措施。